Trial Profile
A retrospective study to evaluate the treatment response to enzalutamide after treatment failure with abiraterone+prednisone in patients with castrate resistant prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Mar 2016
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Mar 2016 New trial record